Biotechnology News and Research

RSS

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Human Gene Therapy articles describe two novel anti-tumor therapies

Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

26 Oct 2012

Study defines complexity of underlying mutations responsible for pancreatic cancers

A large-scale study that defines the complexity of underlying mutations responsible for pancreatic cancers in more than 100 patients was published in Nature today.

26 Oct 2012

Population Health Management discusses latest information on shingles and PHN

Shingles, a reactivation of the herpes zoster (chickenpox) virus affects nearly 1 in 3 Americans. About 1 million cases are diagnosed each year, with some patients suffering excruciating pain and itching due to post-herpetic neuralgia (PHN), a complication of the viral infection that can last for years despite treatment.

26 Oct 2012

American Society of Nephrology establishes new foundation

The American Society of Nephrology (ASN) has announced the creation of a new foundation—the ASN Foundation for Kidney Research—to propel major research advances in the treatment of kidney patients, and reach a cure for a disease that affects millions across the globe.

From Baxter International Inc. 26 Oct 2012

Thrasos completes $35 Million financing for development of THR-184 against AKI

Thrasos Therapeutics announced that it has completed a $35 Million (U.S.) financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

25 Oct 2012

Airport security scanners may affect function of insulin pump or CGM devices

Full-body or X-ray scanners used for airport security screening may affect the function of insulin pump or continuous glucose monitoring (CGM) devices.

25 Oct 2012

Paper details new target for anti-cancer drug development

In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.

25 Oct 2012

New method of testing for West Nile virus

While the United States has largely been spared the scourge of mosquito-borne diseases endemic to the developing world-including yellow fever, malaria and dengue fever-mosquito-related illnesses in the US are on the rise. One pathogen of increasing concern in the U.S. is an arbovirus known as West Nile.

24 Oct 2012

UNM Cancer Center scientist to continue histone modification study

While every one of our cells contains all of our genetic information, each type of cell uses only specific parts of that information to make its proteins. Uncovering more about the mechanism that directs which particular pieces of genetic information the cell uses is the research focus of Mary Ann Osley, PhD, University of New Mexico Professor of Molecular Genetics and Microbiology and Co-Leader of the Cancer Biology and Biotechnology Program at the UNM Cancer Center.

24 Oct 2012

SUNY Downstate to join Neurological Emergencies Treatment Trials network

SUNY Downstate Medical Center has been selected by the National Institutes of Health (NIH) to join the Neurological Emergencies Treatment Trials (NETT) network, which is dedicated to improving emergency care for neurological injuries that require immediate care, such as stroke, seizures, and traumatic brain injury, as well as other illnesses affecting the brain, spinal cord, and peripheral nervous system.

24 Oct 2012

SUNY Downstate to participate in Urban Universities for HEALTH

SUNY Downstate Medical Center has been selected as one of five institutions to participate in Urban Universities for HEALTH (Health Equity through Alignment, Leadership, and Transformation of the Healthcare Workforce), a national initiative that aims to improve the health of urban communities by developing their health workforce.

23 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Austrian researchers receive $7.4 million award to verify new breast cancer pathways

The innovator's award recognises Josef Penninger's work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.

23 Oct 2012

Financial environment presents opportunities as well as challenges

Leading biotechnology executive Dr Deborah Rathjen has called on the industry to look at the opportunities that exist in a post-GFC environment, not just to focus on the negatives.

23 Oct 2012

Lantheus Medical Imaging extends contract to supply molybdenum-99 to Nordion

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that it has extended its contract with Nordion to supply molybdenum-99 (Mo-99) for use in its TechneLite (Technetium Tc 99m Generator) generators. Mo-99 is the parent isotope of technetium-99m (Tc-99m), the medical radioisotope most widely used in nuclear medicine diagnostic imaging tests.

22 Oct 2012

New approach to prevention of breast cancer wins $7.4M award

A new approach to possible future prevention of breast cancer and slowing the spread of tumours has won Austrian researcher Josef Penninger, director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, a $7.4 million innovator's award to continue his research, from the USA's Congressionally Directed Medical Research Program.

22 Oct 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.

22 Oct 2012

EvaluatePharma's Tracking Drugs@FDA provides regulatory approval analysis

EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today launched a new service enhancement, Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA drugs and the related FDA document library as well as FDA Orange Book patent data - all fully integrated into the industry-leading EvaluatePharma platform and analytical tools.

22 Oct 2012